Deargen
deargen.me
Actively hiring
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Deargen is a Daejeon company founded in 2016 that applies deep learning to drug discovery. Its models predict compound and protein interactions and repurpose existing molecules for new indications. The company works with pharmaceutical partners in Korea and abroad on early stage discovery programmes.
News
Report
Serengen and Deargen establish drug discovery collaboration
Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen's novel DNA encoded library (DEL) technology with Deargen's artificial intelligence (AI)-driven drug discovery platform,
Read more
Report
Serengen GmbH: Deargen and Serengen Partner to Accelerate Drug Discovery
Serengen and Deargen are excited to announce their collaboration to accelerate the drug discovery process. This strategic partnership brings together Serengen's novel DNA encoded library (DEL) technology
Read more
Report
Deargen获得1700万美元B轮融资_腾讯新闻
Deargen是韩国一家药物研发商专注于从事基于人工智能技术的基因组数据分析服务致力于发现医疗中的疾病靶点通过设计新药分子实现精准医疗近日宣布在B轮融资中筹集了1700万美元除了Hana ……
Read more
Report
Deargen Annonuces Patent Application for a TNBC Target Novel Drug Candidate Using AI
Using a self-developed AI platform, it takes only 10 weeks from the discovery of the anticancer drug targets to the discovery and synthesis of new compounds.
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.